Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -2,966.00% | 96.90% | 22.21% | 86.09% | 114.82% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 105.88% | -24.62% | -77.16% | -27.31% | -158.98% |
| Total Other Non-Cash Items | 1,154.17% | -101.46% | 131.80% | -90.17% | -345.75% |
| Change in Net Operating Assets | -26.16% | 67.47% | -28.87% | -162.60% | 512.32% |
| Cash from Operations | 42.47% | 41.64% | 7.81% | -361.71% | -20.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -47.62% | -70.41% | 25.00% | 158.05% | -- |
| Total Debt Repaid | -- | -- | -- | -100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -200.00% | -- |
| Cash from Financing | -34.33% | -67.05% | 25.00% | 302.64% | 456.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.90% | -1,258.14% | 136.47% | -687.10% | 159.08% |